X
XENON PHARMACEUTICALS INC
NASDAQ: XENE (Xenon Pharmaceuticals Inc.)
Kemas kini terakhir: 2 jam lalu58.65
-0.15 (-0.26%)
| Penutupan Terdahulu | 58.80 |
| Jumlah Dagangan | 466,752 |
| Harga / Jualan (P/S) | 591.55 |
| Harga / Buku (P/B) | 4.57 |
| Julat 52 Minggu |
| Margin Operasi (TTM) | -969.84% |
| EPS Cair (TTM) | -3.22 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 1.23% |
| Nisbah Semasa (MRQ) | 17.66 |
| Aliran Tunai Operasi (OCF TTM) | -196.85 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -128.49 M |
| Pulangan Atas Aset (ROA TTM) | -22.03% |
| Pulangan Atas Ekuiti (ROE TTM) | -31.60% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | Xenon Pharmaceuticals Inc. | Bercampur | Menaik |
AISkor Stockmoo
-1.2
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 2.0 |
| Purata Bergerak Teknikal | -5.0 |
| Osilator Teknikal | -0.5 |
| Purata | -1.17 |
|
Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. It is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. The product candidates of the group include XEN1101, NBI-921352, and XEN496 for Epilepsy and Nav1.7 oral inhibitors for Pain. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Growth |
| % Dimiliki oleh Orang Dalam | 0.14% |
| % Dimiliki oleh Institusi | 103.51% |
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| SVORONOS DAWN | - | - | 0 | 0 |
| Jumlah Keseluruhan Kuantiti Bersih | 0 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | 0 | |||
| Purata Pembelian Keseluruhan ($) | - | |||
| Purata Jualan Keseluruhan ($) | - | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| SVORONOS DAWN | Pengarah | 01 Sep 2026 | Pelaksanaan pilihan | 5,144 | - | - |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |